No Data
Stocks to watch: promising domestic demand stocks with significant room for recovery.
Yukaria <286A.T> is returning to raising the possibility of supporting the management of medical institutions. While the overall market moves into a recovery phase after a sharp decline, it has potential as a quality domestic demand stock listed on the Tokyo Stock Exchange Growth Market. It supports medical institutions widely, from consulting to fundraising, lending and guaranteeing working capital, factoring of medical fee receivables, and digital transformation (DX). As demand for comprehensive management support Business increases, performance continues to grow significantly.
Yukaria [Emerging Markets Rating List]
"Morgan" <286A> Yukaria OVERWEIGHT maintained * The ratings for each company above are confirmed by us as of 03/31.
Eucalia: Confirmation
Eucalia: Financial Report - 20th Term (2024/01/01 - 2024/12/31)
Yukaria has signed a partnership agreement with Honnikai for comprehensive support in medical management.
On the 27th, Yukaria <286A.T> announced that it has agreed with the Hojinkai Medical Corporation (Hojinkai, Izumi-Otsu City, Osaka Prefecture) to enter into a partnership agreement effective March 31 to provide comprehensive management support for medical operations. With this partnership agreement with Hojinkai (the original Hospital and Seiyu Hospital), the company will provide management know-how, human resource support, and promote the implementation of hospital operations related to appropriate medical DX (digital transformation).
tripla, Daiwa Cycle and others
＜184A＞ The revised forecast for the learning aid has been adjusted downward, with an operating loss outlook of △0.299 billion yen, down from 0.2 billion yen. ＜286A＞ Acquired stocks of Gplus, which engages in Yukaria A-REIT ETF inheritance consulting, making it a wholly-owned subsidiary. ＜4014＞ Concluded a memorandum regarding the consideration of a business partnership with Sumitomo Life Insurance Mutual Company, which operates in the Insurance business. ＜4169＞ Recorded a subsidy income from Enechange of 4.676 billion yen as non-operating income. ＜4591＞ Ribomic JST・CREST "AI App.
